Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial.
Ciqiu YangJunsheng ZhangYi ZhangFei JiYitian ChenTeng ZhuLiulu ZhangHongfei GaoMei YangJieqing LiMinyi ChengKun WangPublished in: Therapeutic advances in medical oncology (2022)
This trial was registered with ClinicalTrials.gov (NCT03243838) on 5 August 2017.